Antiarrhythmic drugs.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000638:Amiodarone / Q000494:pharmacology; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000145:classification; D001073:Aprindine / Q000494:pharmacology; D044482:Benzeneacetamides; D004206:Disopyramide / Q000494:pharmacology; D005424:Flecainide; D006801:Humans; D007700:Kinetics; D008012:Lidocaine / Q000031:analogs & derivatives / Q000494:pharmacology; D008801:Mexiletine / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D011342:Procainamide / Q000494:pharmacology; D011802:Quinidine / Q000494:pharmacology; D016677:Tocainide; D014700:Verapamil / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D044482:Benzeneacetamides; D010880:Piperidines; D008801:Mexiletine; D016677:Tocainide; D001073:Aprindine; D008012:Lidocaine; D014700:Verapamil; D004206:Disopyramide; D011802:Quinidine; D005424:Flecainide; C015970:lorcainide; D011342:Procainamide; D000638:Amiodarone